Abstract
The discovery of Helicobacter pylori (H. pylori), the curved or spiral shaped bacteria, as the main etiologic organism of chronic gastritis, peptic ulcer disease, and gastric cancer was one the most significant discoveries in gastroenterology of the twentieth century. Helicobacter infections promote infiltration of the gastric mucosa by neutrophils, macrophages, and T and B lymphocytes, and leaves the host prone to complications resulting from chronic inflammation. If left untreated, persistent gastrointestinal infections and chronic gastritis may evolve into more severe diseases, such as peptic ulcer or atrophic gastritis. In addition, infection with H. pylori increases the risk of developing gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma. Helicobacter pylori infections are of great concern worldwide due to increasing antimicrobial resistance and high re-infection rates. In the 1990’s scientific evaluation of natural products and ethnomedicines for the treatment of H. pylori infections began in earnest, and many natural products have been investigated over the past 20 years with promising in vitro results. This review highlights these achievements and the classes of naturally occurring compounds with activity against H. pylori. It also points out the critical need of new treatments for H. pylori infections due to increasing global resistance.
Keywords: Helicobacter pylori, ethnomedicine, gastritis, natural products, peptic ulcer disease.
Current Bioactive Compounds
Title:Susceptibility of Helicobacter pylori to Natural Products: Can Past Research Direct Future Drug Development?
Volume: 8 Issue: 3
Author(s): Temitope O. Lawal, Kapil K. Soni, Brian J. Doyle, Bolanle A. Adeniyi and Gail B. Mahady
Affiliation:
Keywords: Helicobacter pylori, ethnomedicine, gastritis, natural products, peptic ulcer disease.
Abstract: The discovery of Helicobacter pylori (H. pylori), the curved or spiral shaped bacteria, as the main etiologic organism of chronic gastritis, peptic ulcer disease, and gastric cancer was one the most significant discoveries in gastroenterology of the twentieth century. Helicobacter infections promote infiltration of the gastric mucosa by neutrophils, macrophages, and T and B lymphocytes, and leaves the host prone to complications resulting from chronic inflammation. If left untreated, persistent gastrointestinal infections and chronic gastritis may evolve into more severe diseases, such as peptic ulcer or atrophic gastritis. In addition, infection with H. pylori increases the risk of developing gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma. Helicobacter pylori infections are of great concern worldwide due to increasing antimicrobial resistance and high re-infection rates. In the 1990’s scientific evaluation of natural products and ethnomedicines for the treatment of H. pylori infections began in earnest, and many natural products have been investigated over the past 20 years with promising in vitro results. This review highlights these achievements and the classes of naturally occurring compounds with activity against H. pylori. It also points out the critical need of new treatments for H. pylori infections due to increasing global resistance.
Export Options
About this article
Cite this article as:
Lawal O. Temitope, Soni K. Kapil, Doyle J. Brian, Adeniyi A. Bolanle and Mahady B. Gail, Susceptibility of Helicobacter pylori to Natural Products: Can Past Research Direct Future Drug Development?, Current Bioactive Compounds 2012; 8 (3) . https://dx.doi.org/10.2174/157340712802762447
DOI https://dx.doi.org/10.2174/157340712802762447 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Precision Medicine and a Patient-Orientated Approach: Is this the Future for Tracking Cardiovascular Disorders?
Current Pharmaceutical Design Potential Treatment of Cardiac Hypertrophy and Heart Failure by Inhibiting the Sarcolemmal Binding of Phospholipase Cβ1b
Current Drug Targets Natriuretic Peptide Testing in Primary Care
Current Cardiology Reviews Current Management of Peripheral Vascular Disease: Where is the Evidence?
Cardiovascular & Hematological Agents in Medicinal Chemistry Walnut Extract Inhibits the Fibrillization of Amyloid Beta-Protein, and also Defibrillizes its Preformed Fibrils
Current Alzheimer Research Frequencies of Single Nucleotide Polymorphisms in Cytochrome P450 Genes (CYP1A2, 2A6, 2B6, 3A4 and 3A5) in a Rwandan Population: Difference to Other African Populations
Current Pharmacogenomics and Personalized Medicine Bariatric Surgery - Effects on Obesity and Related co-Morbidities
Current Diabetes Reviews Chitosan: A Propitious Biopolymer for Drug Delivery
Current Drug Delivery Clinical Use of Neurophysiological Biomarkers and Self-Assessment Scales to Predict and Monitor Treatment Response for Psychotic and Affective Disorders
Current Pharmaceutical Design Fetal Mechanisms That Lead to Later Hypertension
Current Drug Targets Calcium Channel Blockers in Obesity-Related Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Endothelial Therapy of Atherosclerosis and its Risk Factors
Current Vascular Pharmacology Advanced Glycation and ROS: A Link between Diabetes and Heart Failure
Current Vascular Pharmacology Editorial [Hot Topic: Natural Products for the Healthy Heart (Guest Editor : Dipak K. Das)]
Current Pharmaceutical Biotechnology Targeting Heme Oxygenase-1 in Vascular Disease
Current Drug Targets Targeting the Role of Lipoprotein (a) in Stroke
Cardiovascular & Hematological Disorders-Drug Targets New Strategies in Treatment of Mineral and Bone Disorders and Associated Cardiovascular Disease in Patients with Chronic Kidney Disease
Recent Patents on Cardiovascular Drug Discovery Demystifying the ACE Polymorphism: From Genetics to Biology
Current Pharmaceutical Design Aliphatic and Aromatic Oxidations, Epoxidation and S-Oxidation of Prodrugs that Yield Active Drug Metabolites
Current Medicinal Chemistry Pharmacogenetics of Statins Therapy
Recent Patents on Cardiovascular Drug Discovery